Results 131 to 140 of about 10,485 (198)

Comparative efficacy and safety of antiresorptive and anabolic therapies for male osteoporosis: an updated Bayesian network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Li Z, Zhang L, Xue C, Lu C, Wang L.
europepmc   +1 more source

Different Risk Factors of Rod Fracture between L5-S1 and ≥ L4-5 Levels in Adult Spinal Deformity Surgery. [PDF]

Clin Orthop Surg
Kang DH, Park JS, Park SJ.
europepmc   +1 more source

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men

Context: We have previously demonstrated that alendronate reduces the ability of teriparatide to increase bone mineral density (BMD) in osteoporotic men. The underlying basis for this observation is poorly understood. Objective: The primary aim of this
-
core  

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Chen L, Wang Q, Gu M.
europepmc   +1 more source

Conservative treatments for non-surgically managed osteoporotic vertebral compression fractures: a network meta-analysis of long-term pain and quality of life. [PDF]

Osteoporos Int
Chao WC, Chen YH, Shih JC, Cheng B, Hu MH.   +4 more
europepmc   +1 more source

Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database. [PDF]

Arch Osteoporos
Cassez R, Cortet B, Bouvard B, Theis D, Potey C, Manier S, Paccou J, Philippoteaux C.   +7 more
europepmc   +1 more source

Pre-Operative Bone Health in Elective Spine Surgery, From Risk Assessment to Optimization Strategies: A Narrative Review. [PDF]

Global Spine J
Ng MK, Hitchner M, Dalton J, Lee Y, Green WA, Baek G, Mathew J, Eichbaum YK, Hilibrand AS, Vaccaro AR, Schroeder GD, Kepler CK.   +11 more
europepmc   +1 more source

The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide. [PDF]

J Bone Miner Metab
Matsumoto H, Tsukamoto M, Okimoto N, Ikeda S, Tanaka M, Takahashi M, Ikejiri Y, Oha F, Mizuno S, Shigenobu K, Sakai A, Takada J.   +11 more
europepmc   +1 more source

First Reported Use of Recombinant Parathyroid Hormone in Kenny-Caffey Syndrome Type 2: A Case Report and Literature Review. [PDF]

Diseases
Djordjevic Milosevic M, Skakic A, Andjelkovic M, Delgado-Vega AM, Thonberg H, Klaassen K, Komazec J, Kecman B, Jocic N, Björck E, Lindstrand A, Stojiljkovic M.   +11 more
europepmc   +1 more source

Atypical Fracture From Bisphosphonate Use in Hypophosphatasia With Improved Bone Response to Teriparatide Therapy. [PDF]

JCEM Case Rep
Mora Garzon E, Betancourt Zuluaga D, Salazar Ospina JD, López Velásquez S.   +3 more
europepmc   +1 more source